A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-01

Study Completion Date

2027-02-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, researchers will learn for the first time about the safety of a study drug called BIIB145 and how the body responds to it. This is a "Phase 1" study. This kind of study is an early step in clinical research where the goal is to focus on the safety of the study drug. Another goal may be to learn how the study drug is processed by the body. BIIB145 was designed to help people with multiple sclerosis (MS). But, before it can be tested in people with MS, it must first be tested in healthy volunteers to learn about its safety and other effects.

The main goal of this study is to learn about the safety of BIIB145 and how it is processed by the body, with or without food.

The main questions researchers want to answer are:

* How many participants have adverse events and serious adverse events during the study? An adverse event is a health problem that may or may not be caused by the study drug.
* How does BIIB145 affect the participants' overall health?

Researchers will also learn more about:

* How BIIB145 is processed by the body, with or without food.

This study will be done as follows:

* Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which participants will check into the study research center.
* There will be 3 parts to this study.
* Part 1: Participants will take a single dose of BIIB145 or a placebo after not eating overnight. A placebo is something that looks like the study drug but does not contain any medicine. A placebo is also given in the same way as the study drug. Participants in Part 1 will be in the study for up to 42 days.
* Part 2: This part of the study will have a "crossover" design. This means that all participants in Part 2 will all take BIIB145 twice, once with food and once without food. When taken with food, they will finish a meal about 30 minutes before their dose. Without food, they will not eat overnight before taking their dose. But, the order in which they take BIIB145 with or without food depends on the group they are randomly assigned to. Participants in Part 2 will be in the study for up to 56 days.
* Part 3: Participants will take a dose of BIIB145 or the placebo once a day for 14 days. For each dose, participants will not eat overnight before taking it. Participants in Part 3 will be in the study for up to 56 days.
* For Part 1, participants will stay at the study research center for 4 days after screening. There will be 2 other visits to the center to check on participants' health on Day 7 and Day 14.
* For Part 2, at 2 different times, participants will stay at the center for a period of 4 days at a time, after screening. There will be a break of about 7 days between stays. There will be 3 other visits to the center to check on their health on Day 7 (of each period) and on Day 14.
* For Part 3, participants will stay at the center for 17 days after screening. There will be 2 other visits to the center to check on their health on Day 21 and Day 28.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of the study is to evaluate the safety and tolerability of single and multiple ascending doses of BIIB145 in healthy adult participants.

The secondary objectives of the study are to evaluate the pharmacokinetics (PK) profile of single and multiple ascending doses of BIIB145 and its enantiomers in healthy adult participants; and the effect of food on the PK profile of BIIB145.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BIIB145

Administered orally

Intervention Type DRUG

Placebo

Administered orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a body mass index (BMI) between 18 and 32 kilograms per square metre (kg/m\^2), inclusive, and a total body weight \> 50 kilograms (kg) at Screening and Check-In.
* Must be in good health as determined by the Investigator, based on medical history and Screening evaluations. Good health is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead electrocardiogram (ECG), and clinical laboratory tests.

Exclusion Criteria

* History of any clinically significant blood disorders or cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
* History of, or ongoing, malignant disease, including solid tumours and hematologic malignancies (except for basal cell carcinomas and squamous cell carcinomas that have been completely excised and considered cured at least 1 year prior to Check-In).
* Systolic blood pressure \> 150 millimetres of mercury (mmHg) or \< 90 mmHg after resting for 5 minutes in the supine position at Screening and prior to dosing. If out of range, testing may be repeated once at Screening and once prior to dosing.
* Any live or attenuated immunization or vaccination given within 30 days prior to Check-In or planned to be given during the study period.
* Prior exposure to BIIB145 or any lymphocyte-depleting therapy or exposure to any lymphocyte targeting therapy within 3 months prior to Check-In, or at least 5 half-lives or for the anticipated duration of the product's pharmacodynamics (PD) effects, whichever is longer.
* Known lumbar spine deformity, degenerative arthritis of the lumbar spine, history of lumbar spinal surgery, spinal infection, spinal mass or trauma, and/or known evidence on magnetic resonance imaging (MRI) contraindicating lumbar puncture (LP).

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Biogen

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

US Biogen Clinical Trial Center

Role: CONTACT

Phone: 866-633-4636

Email: [email protected]

Global Biogen Clinical Trial Center

Role: CONTACT

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

302HV101

Identifier Type: -

Identifier Source: org_study_id

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Study Design

Study Groups

Part A [Single Ascending Dose (SAD)]: BIIB145 Cohort 1A

BIIB145

Placebo

Part A (SAD): BIIB145 Cohort 2A

BIIB145

Placebo

Part A (SAD): BIIB145 Cohort 3A

BIIB145

Placebo

Part A (SAD): BIIB145 Cohort 4A

BIIB145

Placebo

Part A (SAD): BIIB145 Cohort 5A

BIIB145

Placebo

Part A (SAD): BIIB145 Cohort 6A

BIIB145

Placebo

Part A (SAD): BIIB145 Cohort 7A

BIIB145

Placebo

Part B [Food Effect]: BIIB145 Cohort 1B

BIIB145

Part C [Multiple Ascending Dose (MAD)]: BIIB145 Cohort 1C

BIIB145

Placebo

Part C [Multiple Ascending Dose (MAD)]: BIIB145 Cohort 2C

BIIB145

Placebo

Part C [Multiple Ascending Dose (MAD)]: BIIB145 Cohort 3C

BIIB145

Placebo

Part C [Multiple Ascending Dose (MAD)]: BIIB145 Cohort 4C

BIIB145

Placebo

Interventions

BIIB145

Placebo

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Biogen

Responsible Party

Principal Investigators

Medical Director

Central Contacts

US Biogen Clinical Trial Center

Global Biogen Clinical Trial Center

Other Identifiers

302HV101